📰 Lin Guey News
Lin Guey News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Lin Guey. Real-time updates on events, politics, business and more.
December 14, 2023
First lead candidate to address a solid tumor indication with significant unmet medical need Supportive pre-clinical proof of concept data reported at SITC 2023 that demonstrated feasibility,...
October 31, 2023
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
August 22, 2023
The firms are to evaluate Carsgen's autologous CAR T-cell therapy CT041 with Moderna's off-the-shelf mRNA vaccine candidate in preclinical and Phase I studies.
August 21, 2023
The companies will evaluate Moderna’s investigational Claudin18.2 mRNA cancer vaccine in combination with CARsgen’s Claudin18.2 CAR T cell candidate.
August 21, 2023
A Chinese biotech, CARsgen Therapeutics and Moderna Inc (NASDAQ: MRNA) have collaborated
May 11, 2023
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
April 4, 2023
Closed merger with Sesen Bio and commenced trading on Nasdaq under ticker symbol CARM Cash position as of the closing of the merger with Sesen Bio provides anticipated operating runway through... | April 4, 2023
April 9, 2021
Tyler Jacks, Ph.D., after 19 years. The director role will be taken over by Matthew Vander Heiden, M.D., Ph.D., a professor of biology at MIT and a medical oncologist at Dana-Farber Cancer Institute. He became a member of the Koch Institute in 2010 and took over for Jacks on Thursday, MIT said. Jacks will continue to lead the Bridge Project, which unites bioegnineers, cancer scientists and clinical oncologists from the Koch Institute and the Dana-Farber/Harvard Cancer Center. > Atara Bioth...
April 7, 2021
Dive Brief: David Davidson, a longtime top executive at gene therapy developer Bluebird bio, will join the richly funded biotech startup Tessera Therapeutics as its chief medical and development officer, the latter company announced Wednesday. At Tessera, Davidson will be joined by former Spark Therapeutics and Moderna executive Hari Pujar, who will become chief operating officer, and by Lin Guey, most recently a vice president at Xilio Therapeutics who has been appointed head of rare disease...